Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Shen, Kui ^a   Rice, Shara D ^a   Gingrich, David A ^a   Wang, Dakun ^a   Mi, Zhibao ^c   Tian, Chunqiao ^a   Ding, Zhenyu ^a   Brower, Stacey L ^a   Ervin, Paul R ^a   Gabrin, Michael J ^a   Tseng, George ^b   Song, Nan ^a  

^a Precision Therapeutics Inc ^*  (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; DBI GENE; DRUG RESPONSE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; PMVK GENE; TOP2A GENE;

EID: 84864004791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040900     Document Type: Article

References (38)

1. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, et al. (2009) Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27: 3185-3191.
2. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, et al. (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16: 5351-5361.
3. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
4. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, et al. (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 104: 13086-13091.
5. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734.
6. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685.
7. Andre F, Broglio K, Roche H, Martin M, Mackey JR, et al. (2008) Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 26: 2636-2643.
8. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, et al. (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103: 264-272.
9. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
10. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712.
11. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, et al. (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147.
12. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527.
13. Council NR, editor (1992) Combining information: statistical issues and opportunities for research Washington DC: National Academy Press.
14. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10: 515-527.
15. Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, et al. (2008) Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 28: 1733-1740.
16. Rustici G, Kapushesky M, Kolesnikov N, Parkinson H, Sarkans U, et al. (2008) Data storage and analysis in ArrayExpress and Expression Profiler. Curr Protoc Bioinformatics Chapter 7: Unit 7 13.
17. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
18. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 98: 5116-5121.
19. Andre F, Pusztai L, (2006) Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3: 621-632.
20. Hershko A, (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 12: 1191-1197.
21. Spataro V, Toda T, Craig R, Seeger M, Dubiel W, et al. (1997) Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit. J Biol Chem 272: 30470-30475.
22. Wermuth B, Platts KL, Seidel A, Oesch F, (1986) Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. Biochem Pharmacol 35: 1277-1282.
23. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, et al. (2000) NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275: 5416-5424.
24. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, et al. (2007) Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11: 395-406.
25. Marchitti SA, Brocker C, Stagos D, Vasiliou V, (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4: 697-720.
26. Park JG, Yoo JY, Jeong SJ, Choi JH, Lee MR, et al. (2011) Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice. Circ Res 109: 739-749.
27. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, et al. (2000) Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847.
28. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, et al. (2005) retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23: 7483-7490.
29. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, et al. (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24: 2428-2436.
30. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, et al. (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11: 2625-2636.
31. Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, et al. (2009) Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am J Pathol 175: 1824-1830.
32. Pelicano H, Martin DS, Xu RH, Huang P, (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
33. Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, et al. (2011) First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat.
34. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
35. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
36. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
37. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
38. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.